LIQUIDIA TECHNOLOGIES



Corporate Overview

September 2019

Forward-Looking Statements

This presentation includes, and our response to various questions may include, forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including the filing of an NDA for LIQ861, are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations, except as required by law. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This presentation includes long-term goals that are forward-looking, are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of us and our management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these goals will be achieved and we undertake no duty to update our goals.

Novel products via precise control of drug particles

Late-stage clinical biopharmaceutical company focused on transforming the lives of patients

Preparing NDA

- LIQ861: inhaled dry powder targeting segment of PAH market ($3.7B U.S.)
- Met primary endpoint in Phase 3 and will submit NDA late-2019



LIQ861

Pipeline Growth

- LIQ865: to manage local, post-operative pain for 3-5 days (Phase 1)
- Poised to expand PRINT Technology advantages into future products

Proprietary Technology

- Broadly applicable across therapeutic areas, modalities and routes of delivery
- Fully scaled PRINT® platform offers multiple product advantages

Pulmonary Arterial Hypertension (PAH): New Drug Application (NDA); Decision Resources Group, Landscape & Forecast, PAH, Nov 2018

LIQUIDIA TECHNOLOGIES

Pipeline

Product	Indication	Formulation & Route	Phase 1	Phase 2	Phase 3	Next Key Milestone	Worldwide Commercial Rights
LIQ861[1]	PAH	Dry powder inhalation				Submit NDA late-2019	Liquidia
LIQ865	Local, post-operative pain	Sustained-release injectable				Phase 2 ready end of 2019	Liquidia

1. After consultation with the FDA, we advanced from a Phase 1 trial directly to a pivotal Phase 3 trial and will seek approval under the 505(b)(2) pathway.

Seasoned team with relevant commercial and disease area expertise

Neal Fowler

Chief Executive Officer

Richard Katz, MD

Chief Financial Officer

Robert Lippe

Chief Operations Officer

Robert Roscigno, PhD

Senior VP Product Dev

Ben Maynor, PhD

Senior VP R&D

Jeri Thomas

Senior VP Commercial

Management Employment History Highlights

Lilly · ICAGEN · Ironwood · LUNG BIOTECHNOLOGY · The University of North Carolina at Chapel Hill · The Medicines Company

Johnson & Johnson · Goldman Sachs · Genentech · United Therapeutics Corporation · janssen Pharmaceutical Companies of Johnson & Johnson

LIQUIDIA TECHNOLOGIES

LIQ861 for PAH

PRINT® treprostinil, dry powder inhalation

PAH is a rare, progressive disease that results in right heart failure

Abnormal changes in arteries of the lungs increase pressure in pulmonary arteries

Prostacyclin is essential to normal lung function

- Continually released by lungs to bind local receptors
- Vasodilates the pulmonary arteries
- Relaxes smooth muscle
- Inhibits platelet aggregation

PAH Patient

Prostacyclin Deficiency

PAH Treatment

Prostacyclin Analogs

$1.4B of $3.7B market in prostacyclin pathway in 2017



Sources: Farber *Eur Respir Rev* 2016; Lang *Eur Respir Rev* 2014; Channik *Advances in Pulmonary Hypertension Spring,* 2002, DRG, PH Disease Landscape, Nov 2016; Yen-Chun Lai et al. Circ Res. 2014;115:115-130; Decision Resources Group, Landscape & Forecast, PAH, Nov 2018.

LIQUIDIA TECHNOLOGIES

Goal of prostacyclin therapy is to maximize exposure to highest tolerable level

Local delivery generates fewer off-tissue effects



Current prostacyclin products have clear tradeoffs

Oral = Convenient, but ***with systemic toxicities and minimal symptom relief***

- Increases side effects in GI, Nervous and Vascular systems
- Requires up-titration that can be challenging given side effects

Nebulized = Targeted, but ***provides limited dose range***

- Limits max dose due to throat irritation, adverse events
- Requires water, power, supplies, cleaning and time to dose

Infusion = Effective, but ***systemic toxicities & site pain, limits on lifestyle***

- Delivers continuously via i.v. or s.c. line, 24 hours a day
- Poses potential for infection risk

Source: Decision Resources, Pulmonary Hypertension Disease landscape & Forecast, November 2018.

LIQUIDIA TECHNOLOGIES

Choice of inhaled options is driven by convenience

Tyvaso® share was over 80% of the U.S. inhaled patient population in 2017

TYVASO (treprostinil) INHALATION SOLUTION

- **4x daily**, titrated to target of **54 mcg/dose (9 breaths),** the maximum recommended dose in label
- Most common AEs - **cough**, headache, nausea, dizziness, flushing, **throat irritation, pharyngolaryngeal pain,** diarrhea
- **Wash daily** in warm soapy water (mouthpiece assembly and filter shells)
- **Proprietary nebulizer + 13 additional accessories** listed in patient starter kit

INHALED Ventavis® (iloprost) INHALATION SOLUTION

- **4-10 mins, 6-9x daily**, titrated to target of **5 mcg/dose**
- Most common AEs - flushing, **cough**, headache, trismus, insomnia, nausea, hypotension, vomiting, alkaline phosphatase increased, flu syndrome, back pain, tongue pain, palpitations, syncope, GGT increased, muscle cramps, hemoptysis, pneumonia
- **Wash after each use** in warm soapy water & **boil weekly**
- **Proprietary nebulizer + 10 additional spare parts** listed in patient user guide

Sources: Decision Resources Group, Landscape & Forecast, PAH, Nov 2018; Tyvaso® (treprostinil) package insert 2014; Ventavis (iloprost) package insert 2013.
Tyvaso is a registered trademark of United Therapeutics Corporation. Ventavis is a licensed trademark of Bayer Schering Pharma AG.

LIQUIDIA TECHNOLOGIES

LIQ861 combines Effective + Targeted + Convenient into one product

Treprostinil = Proven efficacy	PRINT® = Deep-lung delivery	Device = Simple, Disposable
Trusted prostacyclin-analog	*Precise, Uniform, Trefoil*	*Disposable & long track record*
		
Proven compound with FDA approvals for i.v., s.c., inhaled and oral routes	**Delivers higher dose levels** than approved inhaled formulations	RS00 Model 8 (DMF # 18418) **Compact, easy inhaler** with established commercial track record

LIQUIDIA TECHNOLOGIES

LIQ861 well-tolerated in Ph1 with no reported SAEs, no MTD reached

Results supported moving directly to pivotal study

- n=57 healthy volunteers
- Single, ascending dose
- Dose proportional response
- No dose-limiting toxicities
- TEAEs related to treatment were mild
- No SAEs
- No MTD was reached



Approx. Capsule (TRE fill wt.)	25 µg	50 µg	75 µg	100 µg	125 µg	150 µg
Approx. Emitted Dose (mcg)	20	40	60	80	100	120
Breaths	1-2	1-2	1-2	1-2	2-4	2-4

Sources: Ph 1 study design: 57 subjects enrolled; 43 on LIQ861, 14 on placebo; each cohort = 8 subjects in 3:1 ratio (LIQ861:placebo) – randomized, placebo-controlled; Royal M, Roscigno R, et al. Preclinical and Phase 1 Clinical Characterization of LIQ861, a New Dry Powder Formulation of Treprostinil [poster]. In: PVRI Annual World Congress; 2018 January 21-24; Singapore, Asia.; treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE), Maximum Tolerated Dose (MTD)

LIQUIDIA TECHNOLOGIES

After consulting FDA, initiated Phase 3 INSPIRE pursuant to 505(b)(2)

Investigation of the **S**afety and **P**harmacology of Dry Powder **I**nhalation of T**re**prostinil

Design	•	Open-label, U.S. multicenter
Population	•	At least 100 WHO Group I (PAH) patients; NYHA Class II, III and IV
Criteria	•	On stable dose of Tyvaso® for ≥3 months (or) taking ≤2 approved non-PGI oral PAH therapies
Primary endpoint	•	**Incidence of TEAEs and SAEs at 2 months**
Exploratory endpoints	•	6 minute walk distance (6MWD)
	•	Sustained treatment transition (Tyvaso® transitions)
	•	NYHA functional class improvement
	•	Quality of life using Minnesota Living with Heart Failure Questionnaire (MLHFQ)
PK Sub-Study[1]	•	Transitions from Tyvaso® in a one-directional crossover to compare bioavailability and PK
Data collection	•	Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 30 months

We will continue to treat patients and collect data in a roll-over safety study

Sources: https://clinicaltrials.gov/ct2/show/NCT03399604; PGI – prostacyclin; TEAEs – treatment-emergent adverse events; SAEs – serious adverse events; Quote from Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator.
1. Adjusting dose levels to comparable Tyvaso® emitted dose

LIQUIDIA TECHNOLOGIES

Enrollment suggests LIQ861 is attractive across disease severity

Faster than expected enrollment driven primarily by interest from Functional Class II add-on patients

		No. Subjects (% of Study) at Month 2 timepoint*		
		Tyvaso® Transitions (N=44)	LIQ861 Add-Ons (N=65)	Overall (N=109)
NYHA Functional Class at Screening	Class II	36 (82%)	36 (55%)	72 (66%)
	Class III	8 (18%)	29 (45%)	37 (34%)
Sustained Therapy at Month 2^		**42 (95%)**	**59 (91%)**	**101 (93%)**

Suggests that LIQ861 may have utility as a first-line prostacyclin

***Preliminary data from INSPIRE at Month 2**; ^Patient withdrawals due to: Adverse Events, Patient Choice, Investigator Decision, Lost to Follow Up; no withdrawals due to clinical worsening

LIQUIDIA TECHNOLOGIES

LIQ861 met primary endpoint at Month 2 in pivotal INSPIRE study

TEAEs observed are consistent with inhaled prostacyclins

- **No SAEs related to LIQ861 at Month 2**
- **TEAEs in ≥ 4% patients all mild to moderate**
- **Have not yet reached an MTD**
  - At Month 2, dosed up to 150mcg capsule strength^
- **93% of patients completed 2-months***
- **Most TEAEs observed during first 2-weeks**
- **Most TEAEs in Add-On patients at 25mcg**
- **Positive trends in exploratory endpoints from initial data at Month 2**

TEAEs at Month 2* in ≥ 4% of Patients Receiving LIQ861	**LIQ861 (tresprostinil)**		
	Transitions (n=44)	**Add-ons (n=65)**	**All Treated (n=109)**
Cough	**13.6%**	**46.2%**	**33.0%**
Headache	**20.5%**	**16.9%**	**18.3%**
Throat irritation	**9.1%**	**16.9%**	**13.8%**
Dizziness	**9.1%**	**10.8%**	**10.1%**
Diarrhea	**4.5%**	**10.8%**	**8.3%**
Oropharyngeal pain	**2.3%**	**7.7%**	**5.5%**
Nausea	**4.5%**	**6.2%**	**5.5%**
Dyspnea	**6.8%**	**4.6%**	**5.5%**
Flushing	**2.3%**	**7.7%**	**5.5%**
Chest discomfort	**2.3%**	**6.2%**	**4.6%**

***Preliminary data from INSPIRE at Month 2**; Serious Adverse Events (SAEs); Treatment Emergent Adverse Events (TEAEs) deemed related to LIQ861; Maximum Tolerated Dose (MTD)
^LIQ861 capsule strength doses 125 mcg and 150 mcg are two capsules but if approved, they could be developed as single capsules.

LIQUIDIA TECHNOLOGIES

Transitioning to LIQ861 may build on known benefits of inhaled treprostinil

Exploratory endpoints presented at ISHLT 2019 and ATS 2019

Tyvaso Transitions	NYHA Class II	NYHA Class III
Physical Activity *6MWD*	**Maintained**	**Increased**
Quality of Life *MLHFQ*	**Improved**	**Maintained**

Median 6MWD *meters*



Median MLHFQ *QOL score*



A five (5) point change in score is the minimal clinically important difference

*__Preliminary data from INSPIRE at Month 2__; Minnesota Living with Heart Failure Questionnaire (MLHFQ); 6 Minute Walk Distance (6MWD); Quality of Life (QoL)

ISHLT 2019 Presentation: Hill N. S., et al. INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)
ATS 2019 Poster: Hill N. S., et al. INSPIRE: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)

LIQUIDIA TECHNOLOGIES

Adding LIQ861 as first prostacyclin earlier in disease may be a viable option

Exploratory endpoints presented at ISHLT 2019 and ATS 2019

Add-on patients	NYHA Class II	NYHA Class III
Physical Activity *6MWD*	**Increased**	**Maintained**
Quality of Life *MLHFQ*	**Improved**	**Maintained**



A five (5) point change in score is the minimal clinically important difference

*__Preliminary data from INSPIRE at Month 2__; Minnesota Living with Heart Failure Questionnaire (MLHFQ); 6 Minute Walk Distance (6MWD); Quality of Life (QoL)

ISHLT 2019 Presentation: Hill N. S., et al. INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)
ATS 2019 Poster: Hill N. S., et al. INSPIRE: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)

LIQUIDIA TECHNOLOGIES

LIQ861 = Pipeline in a PRINT® particle

Potential addressable PH patient populations over time





Source: Decision Resources, Pulmonary Hypertension Disease landscape & Forecast, November 2018.

LIQ865 for Local Post-Operative Pain

PRINT® bupivacaine, sustained-release injectable

Significant unmet medical need for extended, non-opioid pain relief

- ~50%+ of patients report inadequate local post-operative pain relief
- Reducing opioids is a priority for hospitals, payors and FDA
- Improved pain relief and reduced opioid use can drive key metrics, such as faster recovery and time to discharge
- Local anesthetics have known efficacy profile but are limited to 8 hours
- EXPAREL® demonstrates demand for longer acting relief
  - Provides 24-36 hours as reported in practice
  - Generated $331M in 2018 net sales and reportedly used in ~5M patients to date
- Physicians desired 3 to 5 days of pain relief in market research

Sources: Wheeler, 2011; Collins, 2013; Shah 2017; Pacira Biosciences Investor Deck May 2019; EXPAREL package insert; EXPAREL® is a registered trademark of Pacira Biosciences

LIQ865 offers the potential for an optimal product profile

- **Target 3 to 5 days duration of action**
  - Supported by PK & PD data from Ph 1 studies
- **Simple, uniform particles of a single active**
  - Easy reconstitution from a powder
- **Flexible application at the surgical site**
  - Adjustable concentration range to deliver the dose
  - Enables instillation or injection around incision
- **Limited potential for dose dumping**
  - Compatible with co-administration of instant-release local anesthetics

LIQ865: Bupivacaine + PLGA blend



LIQ865 was well-tolerated at all doses with dose proportional PK in Ph1

- Ph1a, healthy volunteers in Denmark
- Single, ascending dose
- No dose-limiting toxicities
- All adverse events were mild to moderate
- C_{max} well below reported thresholds for neurotoxicity and cardiotoxicity
- QST demonstrated pharmacodynamic effect for up to 5 days



Initiated Phase 2-enabling tox studies in March 2019 with Phase 2 trials planned for 2020

Sources: Randomized, double-blind, controlled, single ascending dose, safety, PK ,PD trial of two different formulations of LIQ865 in 28 healthy male volunteers; Quantitative Sensory Testing (QST)

LIQUIDIA TECHNOLOGIES

PRINT® Technology

Compatible with nearly any material, payload and route of delivery

Examples, not exhaustive



PRINT® production has been scaled for clinical and commercial demands

Preclinical and R&D
Highly versatile, flexible

Lab Line 2 (2008)

- Highly agile platform enabling process experimentation
- Ideal for early stage process development

cGMP Process Development
Optimization, scale-up

Lab Line 3 (non-cGMP 2015; cGMP 2017)

- Capable of larger batches with increased process control
- We believe Lab Line 3 is fully cGMP compliant to support product launch

cGMP Production
Repeatable and deployable

Commercial Line 1 (expected 2019)

- Optimized drug substance production process
- Designed for continued market supply and scale

LIQUIDIA TECHNOLOGIES

Conclusion

2019 Milestones

Milestone	Anticipated Timing	
Report LIQ861 Ph 3 two-week safety data from INSPIRE trial	1Q:2019	✓
Report LIQ861 Ph 3 primary endpoint from INSPIRE trial	1Q:2019	✓
Initiate LIQ865 Ph 2-enabling tox studies	March 2019	✓
Report LIQ861 PK results	2Q:2019	✓
Conduct pre-NDA meeting with FDA	4Q:2019	
NDA submission to the FDA for LIQ861	4Q:2019	

LIQUIDIA TECHNOLOGIES

LIQUIDIA TECHNOLOGIES



Thank You